Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. From Wikipedia
The move responds to Hims & Hers' continued distribution of compounded semaglutide despite FDA declarations that shortages were resolved
